<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377583</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2011/24</org_study_id>
    <nct_id>NCT02377583</nct_id>
  </id_info>
  <brief_title>Hypothalamo-pituitary Adrenal Axis Activity and Neuropsychological Consequences in Type 1 Diabetes in Childhood</brief_title>
  <acronym>CORTICODIAB</acronym>
  <official_title>Hypothalamo-pituitary Adrenal Axis Activity: Relation With Neuropsychological Consequences in Type 1 Diabetes in Childhood. The CORTICODIAB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective is to precise the role of HPA axis activity in neuropsychological
      consequences of type 1 diabetes. The investigators hypothesize that hyperactivity of HPA axis
      is associated with higher scores of depression and changes in hippocampal volume and mean
      diffusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Background: Type 1 diabetes could be associated with hyperactivity of
           hypothalamo-pituitary adrenal (HPA) axis. Type 1 diabetes is associated with higher
           frequency neuropsychological consequences as mood disorders and structural changes in
           brain, particularly in hippocampus.

        -  Purpose: To describe the association between HPA axis activity and anxiety and
           depression scores in 6-12 year's old diabetes children.

        -  Abstract: The general objective is to precise the role of HPA axis activity in
           neuropsychological consequences of type 1 diabetes. The investigators hypothesize that
           hyperactivity of HPA axis is associated with higher scores of depression and changes in
           hippocampal volume and mean diffusion.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean of nocturnal urinary free cortisol during 5 days.</measure>
    <time_frame>During 5 days after the inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression (CDI) score</measure>
    <time_frame>At the inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean of awakening salivary cortisol and mean of nocturnal urinary cortisol metabolites during 5 days</measure>
    <time_frame>During 5 days after the inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of glucocorticoid sensitive genes expressed in peripheral blood mononuclear cells.</measure>
    <time_frame>At the inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety (STAI) score</measure>
    <time_frame>At the inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polymorphisms of genes involved in HPA axis activity</measure>
    <time_frame>At the inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hippocampal volume and mean diffusion</measure>
    <time_frame>At the inclusion</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetic children</arm_group_label>
    <description>physical examination
Glucocorticoid sensitivity index
DNA sample
Anxiety and depression questionnaires
depression questionnaire
MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>physical examination
Glucocorticoid sensitivity index
DNA sample
Anxiety and depression questionnaires
depression questionnaire
MRI
Laboratory tests</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      20ml blood sample in order to evaluate:

        -  NR3C1 (GR) gene

        -  NR3C2 (MR) gene

        -  FKBP5 gene

        -  CRH gene

        -  CRHR1 gene

        -  CBG gene
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Age: The investigators will limit the study to children at least 6 years, to ensure
             the successful completion of saliva samples and MRI without anesthesia. The
             investigators limit themselves to prepubescent children do not have to take into
             account the influence of sex steroids on the AC activity.

          -  Gender: Although it is expected differences in hippocampal volume and CA activity
             between boys and girls, the relationship between these two variables is not
             necessarily different for boys and girls. Thus, the inclusion of both sexes in the
             analysis is not necessarily problematic, and will be more informative. So it has been
             finally decided to include boys and girls in the sample of subjects undergoing MRI.

          -  Population control: The constitution of a control group from the siblings will enable
             to study the specific effect of diabetes on anxiety and depression, regardless of the
             children's education mode in the same family environment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic group:

               -  diabetes for 1 year

               -  6-12 year's old

               -  included in ISIS-DIAB protocol.

          -  Control group:

               -  brother or sister of a diabetic children

               -  6-12 year's old.

        Exclusion Criteria:

          -  Per os or inhaled corticoid in the previous month of inclusion.

          -  Acute infectious disease in the previous week of inclusion.

          -  Other chronic disease than diabetes type1.

          -  Psychiatric disorders or psychiatric treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul PEREZ, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal BARAT, Professor</last_name>
    <phone>05 56 79 87 25</phone>
    <email>pascal.barat@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'endocrinologie pédiatrique CHG Bayonne Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <state>Aquitaine</state>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie VALADE, Doctor</last_name>
      <phone>05 59 44 38 74</phone>
      <email>aurelieanne33@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal BARAT, Professor</last_name>
      <phone>05 56 79 87 25</phone>
    </contact>
    <contact_backup>
      <last_name>Virginie SAINTIGNAN</last_name>
      <phone>05 57 82 02 04</phone>
      <email>virginie.saintignan@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie pédiatrique - Hôpital de la mère et de l'enfant - CHU de LIMOGES</name>
      <address>
        <city>Limoges</city>
        <state>Limousin</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne LIENHARDT, Professor</last_name>
      <phone>05 55 05 63 58</phone>
      <email>anne.lienhardt@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cécile ETOUBLEAU-JACOT, Doctor</last_name>
      <email>cecile.etoubleau@chu-limoges.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

